Tags

Type your tag names separated by a space and hit enter

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
J Clin Endocrinol Metab. 2008 Oct; 93(10):3943-9.JC

Abstract

BACKGROUND

The BRAF(V600E) mutation is the most frequent genetic alteration in papillary thyroid carcinoma (PTC). The role of BRAF(V600E) mutation as a poor prognostic factor has been controversially reported in series with short-term follow-ups. In this study we verified the prognostic value of the BRAF(V600E) mutation in PTC patients with a long-term follow-up.

METHODS

We studied 102 PTC patients with a median follow-up of 15 yr. The BRAF(V600E) mutation was analyzed by PCR-single-strand conformational polymorphism and sequencing. The correlation between the presence/absence of the BRAF(V600E) mutation, clinicopathological features, and outcome of PTC patients were evaluated.

RESULTS

The BRAF(V600E) mutation was found in 38 of 102 (37.3%) PTC patients, and was significantly more frequent in patients older than 60 yr (P = 0.02), in advanced stages (P = 0.03), and in cases with vascular invasion (P = 0.02). At univariate analysis the worst outcome for PTC patients was significantly correlated with clinicopathological features (i.e. age, tumor size, extrathyroid extension, lymph node and distant metastases, advanced stage, vascular endothelial growth factor expression, and vascular invasion) and the BRAF(V600E) mutation (P < 0.002). However, at multivariate analysis only the BRAF(V600E) mutation showed an independent correlation with the worst outcome (P = 0.03). Moreover, the survival curves of PTC patients showed a lower percentage of survivors in the BRAF(V600E)-mutated group (P = 0.015).

CONCLUSIONS

In this study the BRAF(V600E) mutation correlated with the worst outcome for PTC patients, who were not only at a higher risk not to be cured but also for death. In particular, the BRAF(V600E) mutation was demonstrated to be a poor prognostic factor independent from other clinicopathological features.

Authors+Show Affiliations

Department of Endocrinology, University of Pisa, Via Paradisa 2, 56124 Pisa, Italy. relisei@endoc.med.unipi.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18682506

Citation

Elisei, Rossella, et al. "BRAF(V600E) Mutation and Outcome of Patients With Papillary Thyroid Carcinoma: a 15-year Median Follow-up Study." The Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 10, 2008, pp. 3943-9.
Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab. 2008;93(10):3943-9.
Elisei, R., Ugolini, C., Viola, D., Lupi, C., Biagini, A., Giannini, R., Romei, C., Miccoli, P., Pinchera, A., & Basolo, F. (2008). BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. The Journal of Clinical Endocrinology and Metabolism, 93(10), 3943-9. https://doi.org/10.1210/jc.2008-0607
Elisei R, et al. BRAF(V600E) Mutation and Outcome of Patients With Papillary Thyroid Carcinoma: a 15-year Median Follow-up Study. J Clin Endocrinol Metab. 2008;93(10):3943-9. PubMed PMID: 18682506.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. AU - Elisei,Rossella, AU - Ugolini,Clara, AU - Viola,David, AU - Lupi,Cristiana, AU - Biagini,Agnese, AU - Giannini,Riccardo, AU - Romei,Cristina, AU - Miccoli,Paolo, AU - Pinchera,Aldo, AU - Basolo,Fulvio, Y1 - 2008/08/05/ PY - 2008/8/7/pubmed PY - 2008/12/17/medline PY - 2008/8/7/entrez SP - 3943 EP - 9 JF - The Journal of clinical endocrinology and metabolism JO - J. Clin. Endocrinol. Metab. VL - 93 IS - 10 N2 - BACKGROUND: The BRAF(V600E) mutation is the most frequent genetic alteration in papillary thyroid carcinoma (PTC). The role of BRAF(V600E) mutation as a poor prognostic factor has been controversially reported in series with short-term follow-ups. In this study we verified the prognostic value of the BRAF(V600E) mutation in PTC patients with a long-term follow-up. METHODS: We studied 102 PTC patients with a median follow-up of 15 yr. The BRAF(V600E) mutation was analyzed by PCR-single-strand conformational polymorphism and sequencing. The correlation between the presence/absence of the BRAF(V600E) mutation, clinicopathological features, and outcome of PTC patients were evaluated. RESULTS: The BRAF(V600E) mutation was found in 38 of 102 (37.3%) PTC patients, and was significantly more frequent in patients older than 60 yr (P = 0.02), in advanced stages (P = 0.03), and in cases with vascular invasion (P = 0.02). At univariate analysis the worst outcome for PTC patients was significantly correlated with clinicopathological features (i.e. age, tumor size, extrathyroid extension, lymph node and distant metastases, advanced stage, vascular endothelial growth factor expression, and vascular invasion) and the BRAF(V600E) mutation (P < 0.002). However, at multivariate analysis only the BRAF(V600E) mutation showed an independent correlation with the worst outcome (P = 0.03). Moreover, the survival curves of PTC patients showed a lower percentage of survivors in the BRAF(V600E)-mutated group (P = 0.015). CONCLUSIONS: In this study the BRAF(V600E) mutation correlated with the worst outcome for PTC patients, who were not only at a higher risk not to be cured but also for death. In particular, the BRAF(V600E) mutation was demonstrated to be a poor prognostic factor independent from other clinicopathological features. SN - 0021-972X UR - https://www.unboundmedicine.com/medline/citation/18682506/BRAF_V600E__mutation_and_outcome_of_patients_with_papillary_thyroid_carcinoma:_a_15_year_median_follow_up_study_ L2 - https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2008-0607 DB - PRIME DP - Unbound Medicine ER -